| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
GRK6-IN-1 targets G protein-coupled receptor kinase 6 (GRK6). GRK6 is a key kinase required for multiple myeloma (MM) cell survival. The compound is a potent inhibitor of GRK6 with an IC₅₀ of 120 nM. It also inhibits GRK7, GRK5, GRK4, and GRK1. GRK6-IN-1 has potential for study in multiple myeloma and triple-negative breast cancer.
|
|---|---|
| ln Vitro |
In vitro, GRK6-IN-1 is a potent inhibitor of GRK6 with an IC₅₀ of 120 nM. It also inhibits GRK7, GRK5, GRK4, and GRK1 with IC₅₀ values of 6.4, 12, 22, and 52 nM, respectively. The compound is used to study the role of GRK6 in multiple myeloma and other cancers. GRK6 is a critical kinase required for MM cell survival.
|
| ln Vivo |
In vivo, GRK6-IN-1 has potential for studying multiple myeloma. However, specific in vivo efficacy data in animal models are not detailed in the available literature.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for GRK6-IN-1 involves measuring the kinase activity of GRK6 in the presence of the compound. The IC₅₀ of 120 nM is determined by quantifying the reduction in GRK6-mediated phosphorylation. Kinase assays typically use radiolabeled ATP or fluorescence-based detection methods. The compound's selectivity against other GRK isoforms is also assessed.
|
| Cell Assay |
In vitro cell-based assays for GRK6-IN-1 involve treating multiple myeloma cells with the compound and assessing cell viability and proliferation. GRK6 is required for MM cell survival, so inhibition of GRK6 is expected to reduce cell viability. The compound's effects on GRK6 downstream signaling pathways are also evaluated.
|
| Animal Protocol |
In vivo animal studies for GRK6-IN-1 would likely involve xenograft mouse models of multiple myeloma. Tumor-bearing mice would be treated with GRK6-IN-1, and tumor growth inhibition would be monitored. The compound's ability to extend survival in MM models would be a key endpoint.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of GRK6-IN-1 are not extensively detailed in the available literature. The compound has a LogP of 5.3. It is soluble in DMSO: ~50 mg/mL (~113.92 mM). For storage, powder should be kept at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for GRK6-IN-1 are available in the provided literature. The compound is for research use only and not for human therapeutic applications. Standard laboratory safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
GRK6-IN-1 is a potent GRK6 inhibitor with an IC₅₀ of 120 nM. It has potential for studying multiple myeloma. It also inhibits other GRK isoforms. Its CAS number is 2677786-61-5.
|
| Molecular Formula |
C22H23CLN6O2
|
|---|---|
| Molecular Weight |
438.91
|
| Exact Mass |
438.157
|
| CAS # |
2677786-61-5
|
| PubChem CID |
163196291
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
560
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1=C2C(C(OC)=CC=C2)=C(NC2C=C(CC)NN=2)N=C1NCC1=CC=C(Cl)C=C1OC
|
| InChi Key |
ACLLLJSNOCYQOJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H23ClN6O2/c1-4-15-11-19(29-28-15)26-21-20-16(6-5-7-17(20)30-2)25-22(27-21)24-12-13-8-9-14(23)10-18(13)31-3/h5-11H,4,12H2,1-3H3,(H3,24,25,26,27,28,29)
|
| Chemical Name |
2-N-[(4-chloro-2-methoxyphenyl)methyl]-4-N-(5-ethyl-1H-pyrazol-3-yl)-5-methoxyquinazoline-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~113.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2784 mL | 11.3919 mL | 22.7837 mL | |
| 5 mM | 0.4557 mL | 2.2784 mL | 4.5567 mL | |
| 10 mM | 0.2278 mL | 1.1392 mL | 2.2784 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
